Kontour (Xi'an) Medical Technology Co (688314) Fair Value & Analysis
Healthcare · CN · Market cap 3.3B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Fair value updated Jul 12, 2026, revised from ¥26.76 to ¥26.38 (−1.4%) since Jun 24, 2026. Share price +7.6% over the past month.
A solid business, but screening 24% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥31.83). The favourable scenario is already priced in.
- Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥17.21 to ¥31.83) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥16.82 – ¥88.57 · fair‑value band ¥17.21 – ¥31.83 · the ¥34.49 price screens above the ¥26.38 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Kontour (Xi'an) Medical Technology Co (688314) currently trades at ¥34.49, while our model-based Fair Value estimate is ¥26.38, implying the stock looks roughly 23.5% overvalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Kontour (Xi'an) Medical Technology Co generated revenue of 342M CNY at a net margin of 25.7%. Revenue declined 10.7% year over year. It earns a return on equity of 12.4%. The balance sheet holds a net cash position of 372M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥17.21 (bear case) to ¥31.83 (bull case); at ¥34.49, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -24%, 688314 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥29.43) versus Asset-Based (¥5.92). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Kontour (Xi'an) Medical Technology Co., Ltd. engages in the research and development, production, and sale of Class III implantable medical devices in China. The company offers products in the fields of neurosurgery cranial repair and fixation, cardiothoracic surgery sternum fixation, and maxillofacial repair.
Full company description
Kontour (Xi'an) Medical Technology Co., Ltd. engages in the research and development, production, and sale of Class III implantable medical devices in China. The company offers products in the fields of neurosurgery cranial repair and fixation, cardiothoracic surgery sternum fixation, and maxillofacial repair. It also provides oral bone repair materials, oral absorbable biofilm, implant system, and other tools. In addition, the company offers repair and fixation products that include traditional titanium materials, high-end PEEK materials, and absorbent polymer materials; PEEK4D bioactive plates; PEEK bone plates, titanium mesh plates, PEEK link plates, PEEK screws, titanium link plates, test molds, bone plugs, bone mesh, bone plug strips, disposable brain drainage devices, supporting surgical tools, and other complete products for skull repair and fixation surgery process. Kontour (Xi'an) Medical Technology Co., Ltd. was founded in 2005 and is based in Xi'an, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kontour (Xi'an) Medical Technology Co reported revenue of ¥350M in FY2025 versus ¥213M in FY2021, a compound +13.2%/yr. Reported net income was ¥98.8M in FY2025, compounding +4.9%/yr from FY2021.
688314 screens 24% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Kontour (Xi'an) Medical Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kontour (Xi'an) Medical Technology Co (688314) overvalued or undervalued?
What is the fair value of 688314?
What is the quality score of 688314?
What is the revenue of Kontour (Xi'an) Medical Technology Co (688314)?
What is the net profit margin of 688314?
Does Kontour (Xi'an) Medical Technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kontour (Xi'an) Medical Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.